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Abstract 
Background: Primaquine (PQ) is the only FDA-approved drug for radical cure of Plasmodium 
vivax (P.v) malaria, but treatment can result in life-threatening hemolysis if given to a glucose-6-
phosphate dehydrogenase deficient (G6PDd) patient. Therefore, the G6PD status of the patient 
with P.v must be known prior to prescribing PQ. However, patient G6PD status in rural malaria 
endemic settings is generally unknown, illuminating the need for reliable point of care G6PD 
diagnostic tests as a prerequisite to safely administer PQ. To increase community PQ access in 
Cambodia, performance of CareStart™ G6PD rapid diagnostic tests (RDTs) needs to be 
evaluated in healthcare workers (HCWs) and village malaria workers (VMWs).  
Methods: Training materials on G6PD and PQ were developed for HCWs and VMWs and each 
performed G6PD RDT test on 8-12 adult male volunteers, with pre- and post-training 
questionnaires completed by trainees and G6PD test volunteers. The performance of CareStart™ 
RDT for G6PDd screening was assessed against a quantitative G6PD lab test (Pointe Scientific, 
Inc. MI, USA). Descriptive and inferential statistics were used to analyze the data. 
Results: 94 trainees and 960 G6PD volunteers were recruited in Oddar Meanchey province, 
Cambodia from December 2017 to February 2018. Of the 960 volunteers, 156 (16%) were G6PD 
deficient based on a quantitative test activity threshold of 30%. The sensitivity, specificity, PPV 
and NPV of CareStart™ RDT were 96.8%, 95.5%, 80.2%, 99.4% for HCW/VMW trainees vs. 
96.2%, 97.2%, 86.7%, and 99.3% for trained study staff in the field and 94.2%, 98.8%, 93.6% 
and 98.92% for experienced laboratory staff, with no statistical difference among the groups. The 
mean knowledge score pre-training was 33.9% (VMWs) and 56.4% (HCWs), with improvement 
to 89% and 90% post training (p <0.001). Improvement in the HCW/VMW’s knowledge scores 
was independent of years of experience, profession and education level. Perception of PQ risk 
based on RDT results was assessed pre-and post-training. 
Conclusions: With minimal training, CareStart™ RDT is highly specific, feasible and a practical 
option for the identification of G6PDd male patients and its use may enable safer prescribing of 
PQ to decrease the burden of P.v relapse. 
Keywords: Malaria, G6PD, Primaquine, Rapid Diagnostic Test  
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Background  
 
           Despite joint efforts by the national malaria control program and various international 
partners working towards malaria elimination in Cambodia, these efforts continue to be a 
challenge in this resource-limited setting. Progress has been hampered by antimalarial drug 
resistance, and lack of access to curative doses of Primaquine for the treatment of Plasmodium 
vivax. However, Primaquine (PQ) which is currently the only Food and Drug Administration 
(FDA) approved drug that can eliminate hidden reservoir of P.v infections in the liver and 
prevent frequent relapses, can also cause significant life threatening hemolysis if wrongly given 
to a glucose-6-phosphate dehydrogenase (G6PD) deficient patient (Seidlein et al. 2013; Roca-
Feltrer A, Khim N et al. 2014).).  
           The World Health Organization (WHO) estimates that one million people are infected 
annually with malaria (Population Reference Bureau, 2016). Among different malaria species in 
Southeast Asia, Plasmodium vivax (P.v) accounts for 46% (26,183) of all malaria cases in 
Cambodia (Sovannaroth, S et al. 2016). Cambodia’s National Malaria program (CNM) estimates 
that the number of malaria outbreaks decreased. However, malaria remains as a major cause of 
morbidity in Cambodia and requires a robust system and malaria management program to ensure 
a successful elimination strategy (Population Reference Bureau, 2016).  
               G6PDd is one of the most common defective human enzymes affecting close to 400 
million individuals worldwide. It is an X-linked genetic disorder that results in impaired enzyme 
activity in erythrocytes (Gonzalo et al. 2013). G6PD enzyme protects erythrocytes against 
oxidation by generating a reduced form of nicotinamide adenine dinucleotide phosphate 
(NADPH). G6PDd a mutated G6PD gene, affects erythrocyte cell stability, especially when 
exposed to 8-aminoquinoline drugs such as PQ required for cure of patients with P.v.  Easy to 
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use, reliable, and easily accessible screening for G6PDd is needed before PQ can be administered 
safely (Amoah et al. 2016; Sovannaroth et al. 2016).   
                     At the moment, the Cambodian National Strategic Plan for Elimination of Malaria 
(CNM, 2011-2015) has procedures and strategies in place for training providers in the diagnosis 
and treatment of malaria, but not for G6PDd screening, or the use of G6PD rapid diagnostic tests 
(RDTs) at the community level (CNM, 2011). Despite reports of decreasing Plasmodium 
falciparum (Pf) malaria in Cambodia, P.v elimination poses continued challenges, and the 
country’s economic status is not well equipped to handle the needed costs for implementing 
needed strategies and carrying out sustainable practices to ensure P.v elimination by 2025, the 
goal set by the Cambodian government and WHO (WHO, 2015). Inexpensive G6PD screening 
tests could increase access to radical curative doses of PQ but their reliability needs to be 
assessed in the field settings to ensure safe deployment at appropriate level of care.  
Demographics of the country 
           Cambodia is located in Southeast Asia, covering an area of 181,040 sq. km, and shares 
borders with Vietnam, Laos and Thailand. Current population is 15,840,251. It has 25 provinces 
and 13,406 villages (WHO, 2003; CNM, 2011). Public health centers provide basic medical care 
for a small charge, such as $0.12 per visit for the out-patient department and a $5 charge for in-
patient care (Chu et al. 2017). Neither private nor government health insurance is generally 
available, particularly in rural areas (Sovannaroth et al. 2016) (Appendix A).             
Geographical distribution  
Currently, malaria elimination is a national priority with goals of eliminating P.f by 2020 
and P.v malaria by 2025 (Canavati et al. 2013). The prevalence of G6PDd in Cambodia has been 
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reported to be between 13-26% in males and 3-4% in females (Khim et al. 2013; Sovannaroth et 
al. 2016).  
Problem Statement 
          G6PD status of P.v patients must be known prior to prescribing PQ treatment in order to 
avoid potentially life-threatening hemolysis from standard doses of PQ. The safe treatment for 
P.v malaria depends on the reliability of results for G6PD screening, yet available screening tests 
have not been evaluated in the field settings (Jalloh et al. 2004). In addition, the number of 
studies evaluating the performance of G6PD RDT in Cambodia are relatively few, and prior kits 
were only formatted for laboratory and temperature controlled settings (USAID, 2012). The 
national malaria treatment guidelines for Cambodia recommended treatment of P.v patients with 
PQ since 2012, with precise guidelines updated in 2014 (Sovannaroth et al. 2016). Despite these 
recommendations, PQ is still not widely used in Cambodia due to the unavailability of reliable 
G6PD diagnostic-field tests, unavailability of PQ, and insufficient data on how to train staff to 
perform G6PD RDT tests safely.   
           Recent published data suggested that a new 3rd generation CareStart™ RDT may be more 
suitable for field-testing, which might allow treatment implementation with PQ in patients with 
P.v malaria (Roca-Feltrer, A. et al, 2014). However, to date, most testing of CareStart™ have 
only been done in the laboratory settings by trained laboratory staff or by research investigators 
(Gonzalo et al. 2013). In addition, the level of training that is required for novice users of G6PD 
testing kits has not been established.    
Purpose 
            The purpose of the study was to assess the performance of the CareStart™ in the hands of 
HCW/VMWs in the field settings and compare it with the results from trained study staff 
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(expert/observers) in the field and lab RDT, vs. the quantitative reference test (Ponte Scientific, 
Inc. MI, USA). To achieve this, training materials were developed to teach HCWs, VMWs, and 
lab technicians on how to reliably screen patients for G6PD using the CareStart™, and provide 
standardized counseling to patients based on their G6PD results. The study also intended to 
evaluate HCW/VMWs based on their ability to correctly perform and interpret the G6PD RDT 
results, as well as their effectiveness in counseling G6PD test volunteers.  
         Specific Aims 
 Develop training materials to improve knowledge and acceptability of PQ use in G6PD 
normal patients and assess the performance of the CareStart™ for G6PDd screening in 
the field settings in the hands of HCWs and VMWs. 
 
 Compare the performance of CareStart™ for G6PDd screening in the field setting in 
the hands of the HCW/VMWs vs. trained study staffs (expert observers) in both field and 
laboratory settings.  
 
 Develop PQ treatment related counseling materials to educate patients regarding risks  
and benefits of PQ in malaria case management.  
 
 Assess HCW/VMW’s knowledge of PQ, and their acceptability to assess the G6PD status 
of malaria patients seen at their health centers, and willingness to prescribe PQ.  
Research Questions 
Among HCW and VMW with varied levels of education:  
 Does standardized training and education on the safe use and deployment of CareStart™ 
for G6PD screening result in comparable rates of correctly tested and interpreted RDTs, 
and improve their knowledge?  
 How do the field RDT results compare with the results obtained in controlled settings in 
the laboratory and against the gold standard quantitative testing?  
 Does education and training improve the willingness of HCWs/VMWs to give PQ post 
training?  
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 Does education and training improve acceptability levels of malaria workers to test for 
G6PD among malaria patients 
Significance 
           PQ is the only FDA-approved drug that can provide radical cure from P.v. However, to 
receive PQ, patients must be G6PD normal to prevent drug-induced hemolysis. Due to the 
limited availability of diagnostic testing for G6PD in Cambodia, most patients only receive 
treatment that eliminates malaria from the blood, without killing the liver stage parasites 
(hypnozoites) (Khim et al. 2013). There is insufficient data in regards to modified PQ dosing 
regimens for G6PDd patients in Cambodia that would make PQ safe for use in a wider scale. 
Therefore, in order to use PQ in Cambodia, patients must be screened for G6PDd, and the 
performance of these tests must be evaluated in the field and at the level of HCW/VMW 
responsible for treating patients with malaria, before deploying PQ at these lower levels of care.    
              There is therefore an urgent need to identify G6PD screening tests that can be deployed 
at the point of care, often at the village level, where patients with malaria seek care. Although a 
field study assessing the performance of the available CareStart™ G6PD rapid diagnostic test 
(RDT) was conducted in Cambodia in 2012, this was done in controlled laboratory setting, and 
therefore uncertainty remains on how well CareStartTM RDT will perform when deployed in ‘real 
world’ setting (Roca-Feltrer A, Kim S et al. 2014, 2012). The level of training and supportive 
supervision required to effectively train village malaria workers (VMWs) and health center staff 
on the correct use and interpretation of the RDTs have also not been fully assessed. Neither has 
the acceptability among HCW/VMWs to incorporate G6PD test at the community level and their 
acceptability to prescribe and give PQ given its potential risks. In addition, since G6PD 
deficiency is bimodal with most G6PD deficient males having G6PD activity levels of <30%, 
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WHO recommends that appropriate G6PD point of care tests should be able to detect all G6PD 
deficient males with <30% activity. There is insufficient data if this can be achieved with 
CareStart™ in the field settings, despite the promising results from the laboratory settings. Given 
the potential risks associated with incorrect diagnosis of G6PD status, it is possible that use of 
G6PD RDTs in a community setting might not be appropriate, but additional data is needed. 
The WHO and National Center for Parasitology, Entomology and Malaria Control 
(CNM) cautioned that the deployment of RDTs for G6PD should be piloted to evaluate RDT 
performance in real-life field settings, which will ensure safe generalization of the program to the 
Cambodian public.  In addition, WHO (2015) stated that there is a need to evaluate feasibility, 
effectiveness and acceptability of CareStart use at the HCW and VMW implementation levels in 
the field settings, to address the knowledge gap. 
Literature Review 
        Scopus, PubMed and Web of Science were searched for peer-reviewed studies published 
between 2001-2017 in the English language using the key terms “malaria or P. vivax”, “G6PD 
deficiency”, “RDT testing”, “CareStart RDT G6PD testing”, Point-of–care systems”, “healthcare 
worker or malaria village worker training”, “Primaquine”, “PQ”, “Cambodia”, “malaria 
elimination”. Studies were selected if they addressed or evaluated healthcare provider training 
and G6PD RDT testing to assess for G6PDd. A total of 48 articles met search criteria.          
             Von Fricken et al. (2014) conducted a study to test the sensitivity, specificity, positive 
predictive value (PPV), and negative predicative value (NPV) of 2nd generation CareStart™ in 
the Haitian community. They screened a total of 456 participants, 267 females and 189 males all 
healthy subjects. The kit generated sensitivity of 90% and NPV of 98.2%. This study concluded 
that the 2nd generation testing kit was highly specific and effective at determining those with 
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normal G6PD enzymatic activity in controlled temperature settings. However, the study only 
used venipuncture blood samples, not finger prick samples, and only reported the results on a 
very small number of deficient samples.  
          Another qualitative study was done by Roca-Feltrer et al. (2014) using (FST) fluorescent 
Spot test. The study discovered that G6PDd prevalence rates and enzyme activity in malaria 
patients are consistent with those in healthy individuals. This is important as these findings 
suggest that testing for deficiency can be done at the time of acute malaria or before the 
diagnosis of malaria is made. In addition, Khim et al. found that 2nd generation CareStart™ 
reliably detected deficiencies if the enzymatic activity was less than 30%. The results yielded a 
sensitivity of 84.8%, specificity 93.7%, NPV 98.2% and PPV 60% noting that “the low PPVs… 
were affected by the relatively low prevalence of severe G6PDd … in the sample population and 
should not represent an impediment to the use of this RDT” (Von Fricken et al. 2014). Despite 
the authors not stating temperature settings of this study, they recommended that HCW and 
VMW should be equipped with tools to test for G6PDd.  Both Khim et al and Brenden & Jitthai 
(2012) agreed that the potential cost of RDT implementation into malaria management might be 
a deterrent to meeting this goal. None of these tests evaluated the performance of CareStart at the 
proposed end user level.   
Cost 
        Kyaw et al. (2016) discussed the importance of cost analysis during a pilot study in 
Myanmar to assess sustainability of the program. The authors concluded that annual cost of 
supporting similar studies though sustainable in comparison with previous testing kits are 
affected by the design of study, location (remoteness) and the ability to carry out surveillance 
activity. In their study, up to 60% of the study finances were allocated to the supervisory work.  
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         Brenden and Jitthai (2012) also conducted a study on Evaluation of Malaria control in 
Cambodia. The study assessed the cost of point of care (field) testing, and suggested that cost 
should be leveraged based on provinces and not calculated for the whole country as this might 
increase the overall cost. The authors suggested that the sustainability of VMW should be 
assessed before training to ensure there is longevity of benefit to the healthcare facilities for 
those trained. Kyaw et al. (2016) explained that despite the seemingly minimal cost of 
CareStart™ kit and cost of treatment, (US$ 0.3 per RDT performed and US $0.5 per treated 
patient) this cost is still not easily attainable for low income earners who make an average of $30 
(thirty) dollars to $140 per month (Kyaw et al; Carmichael, 2015).  
CareStart™ RDTs 
Kim et al’s conducted a study in Pailin, west Cambodia using CareStart™ 2nd generation. 
The test was carried out in a temperature-controlled research setting. At the time, CareStart™ 
falsely identified thirty-one (31) patients as “normal” when the subjects were G6PD deficient 
based on the quantitative test done. The sensitivity and specificity was 68% and 100% 
respectively. In 2012, the 3rd generation of CareStart™ was tested against the lab controlled 
gold standard (quantitative test), and it showed sensitivity of 100% and specificity at 97.7% 
compared to the quantitative assay among people presenting with G6PDd and <3.6 U/g Hg 
enzymatic activity (Roca-Feltrer et al. 2014). Based on the results of this study and other 
literature reviews, CNM made plans to deploy this 3rd generation RDT.  Therefore, this study 
will help CNM implement 3rd generation CareStart™ if the results of this study can be replicated 
in the field setting, in the hands of the HCW/VMWs. Roca et al. previously noted that the 
reliability of CareStart can be compromised if done outside of the manufacturers’ specified 
temperatures of 18 °C to 32 °C (64.4°F- 89.6°F).  
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G6PD Testing 
          G6PDd is widespread across malaria endemic areas like Cambodia (up to 26%). WHO; 
Roca-Feltrer et al. 2014; Harvey and Bell, 2008; and Kim et al. (2011) all emphasized the 
importance of screening for G6PDd in Cambodia.  The authors stressed the importance of 
ensuring feasibility and establishing appropriate endpoints for evaluating interventions. Roca-
Feltrer et al’s study included 938 adults with variable G6PDd levels, from moderate to severe. 
The authors concluded that the newer, more user friendly tests (3rd generation CareStart™ ) can 
effectively identify G6PDd subjects and aid in the efforts of eradicating P.v as it allows treatment 
for majority of patients with P.v malaria, thus lowering P.v re-infection rates in the country.  
           In addition, Khim et al. enrolled 2,408 patients mainly from W. Cambodia in a bid to 
study their G6PD status. Selected mean age was 26.7 years (range 2–81), ratio of males to 
females was 3.9:1, of which 40.1% had P.v. The mean G6PD activity was 11.6, with close to 
14% being G6PDd (335/2,408). This study concluded that deploying PQ in Cambodia should be 
preceded by PQ safety studies paralleled with evaluations of easy-to-use tests to detect G6PDd 
(Khim et al. 2013).  
           Theerathananon, Francois, Zongram & Kanchanakhan (2016) also surveyed 102 subjects 
for G6PDd screening and assessed various variables including “demographic data, current 
illness, malaria knowledge, malaria infection history, symptom, medication and prevention by 
using questionnaire and in-person interview”. This study concurred with Khim et al’s claim that 
men are 20% more likely to be G6PDd as opposed to females (13%). The study also indicated no 
statistical difference in malarial infection between patients with normal G6PD versus those who 
are G6PDd.  
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Health worker Training (Appendix B) 
           Seidlein et al. (2013) assessed educational barriers and efficiency in RDT testing as this is 
crucial for P.v elimination. The study showed that the performance of RDTs for G6PDd 
screening has improved over the years. After training some malaria workers in Cambodia, 
USAID (2010) concluded that approaching healthcare trainers as future trainers, and instructing 
them as potential educators yielded the most participation and scored higher post-training in 
teach-back. USAID noted that engaging the private sector when projects target low-income areas 
caused a higher turn-out from local healthcare staff and patients. Greater sustainable results were 
also achieved when healthcare trainees were encouraged to give feedback.  As part of their input 
to healthcare training, the President’s Malaria Initiative (PMI) developed several objectives for 
Cambodia to be met by 2015, a process that is still pending. Some of these objectives include 
advising the national malaria program on how to “perform risk-benefit analysis to inform 
decision-making on administering or withholding radical cure when a patient’s G6PD status is 
unknown, … testing for and interpreting G6PD tests and managing risk of hemolysis when PQ is 
administered when G6PD status in not known” (WHO, 2015). Therefore, PMI supports training 
of HCW and VMW to carry out the said objectives with the hope of making G6PD RDT testing 
standard practice for malaria diagnosis and treatment (PMI, 2016). 
Theoretical foundation for the development of study 
          The behavioral change communication (BCC) framework is a methodology that 
emphasizes the use of dialogue and attempts to explain and predict health behaviors by focusing 
on the attitudes and beliefs of individuals. To effectively implement the objectives of this study, 
both BCC and Roll Back Malaria (RBM) initiatives should be engaged (RBM, 2012). 
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          Roll Back Malaria (2012) objectives employ the concepts of BCC methodologies that 
emphasize the use of dialogue and participation. RBM “uses communication as an overarching 
term to describe a planned process for influencing actions or responses among specific groups of 
people” to enhance program effectiveness (RBM, 2012). One of the ways RBM will be utilized 
is by increasing the health care provider’s’ knowledge on malaria, G6PDd, risks and benefits of 
PQ treatment, and how to use RDTs for G6PD screening through standardized teaching materials 
and hands on training (Acosta et al. 2014) (Appendix C). 
Behavioral Change Communication (BCC) 
           The success of BCC goals relies on effective coordination and organization. BCC 
theoretical framework is useful in bridging the gaps between successfully P.v eradication and 
elimination through the training of both HCW and VMW. BCC promotes individual behavior 
change, supportive environments… [and is a] key component of many malaria programs (Acosta 
et al. 2014). BCC is also a collaborative process that helps create a bridge in communicating with 
the communities. These steps in communication promote positive behaviors and are conducive 
for positive outcomes. However, some authors are conflicted by studies that have incorporated 
BCC, as these studies showed inadequate proof in regards to the benefits of BCC. However, 
Acosta et al. claim that BCC is more beneficial when incorporated with malaria eradication 
frameworks such as Roll Back Malaria. In the context of BCC, the success of this project relies 
on the program organizers directly engaging the community and having the HCW/VMW lead in 
the activities and distribution of educational materials. The benefit of this process relies on the 
trust and communal bond that already exists between the villagers and malaria workers. As an 
additional level of complexity, it was unknown at the time what role VMW can play in G6PD 
screening, and if they can grasp the deployment of RDTs for G6PD without compromise of test 
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results and thus affecting participant’s safety. Hopefully, communication and engaging 
community involvement might help when the pilot study is implemented (Appendix D). 
Identifying Variables 
           Assessing the strategies that contribute to malaria elimination and improving clinician’s 
adherence to standards of practice based on national guidelines is vital for the project’s success. 
Some of the variables included were demographic data, knowledge on G6PD and PQ, malaria 
infection history, medication prescribing practices, and effectiveness of education using 
questionnaire and teach-back (Appendix E); (Figure I). 
Methods 
Design 
          Quasi-experimental study was conducted in the P.v prevalent villages of west Cambodia, 
where deployment of PQ is planned by CNM.  Two primary reasons for choosing this design are: 
1) it was a good fit to answer the proposed research questions; and 2) it was realistic and 
feasible. The study assessed the feasibility and performance of VMWs and HCWs in using and 
interpreting the 3rd generation CareStart™ over an 8-week period. At the workshop, we assessed 
HCW/VMWs’ hands-on-practice using CareStart G6PD RDT. The trainees were observed and 
evaluated four to six times at the end of the 2-day training, with each G6PD test performed using 
commercially available G6PD deficient and G6PD normal control samples. Post-training in the 
field setting, each trainee tested 8-12 G6PD volunteers. VMWs and HCW completed a survey 
(questionnaire) on day 1, Day 2 and at the end of each G6PD testing day to assess their ability to 
retain the knowledge they received during training, explore their willingness to use CareStart™ 
RDT and make PQ treatment decisions based on the RDT results.  
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Study Sites and Population 
           This study was conducted in West Cambodia whose ethnic composition is primarily Khmer.  
The location is relatively poor, agrarian (rice, rubber, corn, vegetables, cashews, tapioca), with 
almost 75% being farmers and loggers. Cambodians average annual income is approximately 
3,735 USD. Most of the people living in this area have either a primary and secondary level of 
education (Grade 1-6 and Grade 7-9), and statistics show that 100% of individuals aged 15 or older 
can read and write. (CIA, 2008). 
The target population: The study population consisted of two groups: (1) VMWs, HCWs 
(nurses, laboratory technicians) and (2) G6PD blood donor (G6PD test) volunteers who reside 
in these malaria endemic villages of west Cambodia.  
Sampling Plan 
        The study utilized convenience sampling method. 
Inclusion criteria: 
 HCWs/VMWs working in Cambodia, Oddar Meanchey Province (Anlong Veng and 
Trapang) 
 Healthy male volunteers at least 18 years old.  Only male test volunteers were screened, 
since females can have 2 populations of red blood cells simultaneously, G6PD normal 
and G6PDd, and the distribution of G6PDd and G6PD normal red blood cells (RBCs) is 
determined at random. CareStart™ kit cannot identify “intermediate” females, who have 
a mix of normal and deficient cells. RBCs with G6PD normal activity produces G6PD 
normal result, however following PQ administration, the fraction of G6PDd RBCs are 
subject to drug-induced hemolysis, which can result in a drop in hemoglobin level 
(Thriemer et al. 2017; Malar J. 2017). Presently, only quantitative tests can provide 
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results on the actual G6PD levels and thus reliably identify those females who are G6PDd 
with activity of 30 - 70% (WHO, 2004).  
Exclusion criteria: 
 HCWs or VMWs not able to understand spoken and written Khmer 
 Patients with severe illness requiring immediate hospitalization and treatment 
 HCWs/VMWs not able to stay for the duration of the study  
Sample size  
           Formal sample size calculations are not required for feasibility studies. However, to 
calculate the ideal sample size, assuming a small effect size (Cohen’s d of 0.30) (we did not expect 
to see greater difference in knowledge score or ability to correctly test and interpret CareStart 
G6PD RDT results between HCWs/VMW and expert reading as per Khim et al. 2013), the power 
of 80%, with alpha of 0.05, the study would require G6PD test volunteer sample size of 139. For 
this study, up to 150 health-worker trainees were recruited and104 enrolled.  
          However, previous studies conducted in Cambodia reported G6PD prevalence in males of 
15%. The sensitivity of G6PD RDT tests to detect G6PDd (<30% enzyme activity) in ideal lab 
conditions was expected to be 99 to 100% based on Roca-Feltrer (2014). Therefore, to detect a 
difference in the test sensitivity from 99% (ideal) to 95% (trainees), it required a sample size of 
1560 (80% power using 5% two-sided test) and 15% prevalence of G6PDd. In this population of 
15% G6PDd, to detect 4% difference in the prevalence of G6PDd (15% vs. 11%), when the test is 
conducted by expert readers (trained study staff) vs. trainees, the minimum sample is 1274 
volunteers (80% power, 5% two-sided test). 
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Setting 
            West Cambodia, border of Thailand, a malaria-high zone area. The targeted healthcare 
facilities and village areas have approximately 800-1000 patients seen at these facilities on a 
monthly basis. Participants were enrolled from the district referral hospital, approximately 11 
health centers, 1 Health Post and multiple VMW posts at or near Anlong Veng and Trapang Prasath 
district, Oddar Meanchay Province in Cambodia. The healthcare facilities have 33 HCW and the 
province has 174 VMW (covering 50 villages). 
 Study duration 
           The entire study was planned to be carried out over a 12-month period to allow for 
development of training manuals, Data Collection Forms, consent forms, survey forms and 
training of malaria workers; however, individual participation of HCW/VMW lasted no more 
than 3 months for trainees, and one day for G6PD test volunteers (Table A). 
Recruitment of participants  
           The Armed Forces Research Institute of Medical Sciences (AFRIMS) team in Cambodia 
advertised the screening on public notice boards with the authorization of the village chiefs. 
Meetings were held with the ministry of health and Malaria Elimination program representatives. 
G6PD test volunteers were screened, consented and enrolled by AFRIMS study team. Patients 
seen at the health centre who met the inclusion criteria were recruited as G6PD test volunteers by 
study team and trainees. Trainees were recruited from there working stations (VMW locations 
and healthcare centres). Each trainee was required to obtain a signed supervisors note to enrol in 
the study (Appendix I; Appendix F). 
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Informed consent Process  
           Written Informed Consent form (ICF) was obtained from HCW/VMWs and every G6PD 
test volunteer prior to study participation. The completed ICFs were retained by the investigators 
as part of the study records and a copy was provided to each study volunteer. All ICFs were 
translated into the local language (Khmer). For the illiterate volunteers, the consent form was read 
to them in Khmer in the presence of a witness who then signed and dated the consent form in the 
presence of the participant. The participant then thump printed the ICF in the allocated line 
(Appendix G). 
Intervention  
           The study was carried out in 2 phases.  During Phase 1: training materials were developed 
and training provided to the HCWS/VMWs using the tools developed. All trainees had to pass 
the knowledge test (Appendix H). In Phase 2: the trainees screened G6PD volunteers using 
CareStart™ RDT. All trainees had to correctly read and interpret the results for each test done.  
Instrument and Measurement 
         A Power-Point training manual on G6PD and PQ (dose, risks and benefits) was developed 
for use at the workshop together with a standardized questionnaire to help assess knowledge, 
acceptability and perceptions of the trainees in regards to PQ use and CareStart RDT. AFRIMS 
professional medical linguists translated all questionnaires from English to Khmer. The 
translations were authenticated and certified. The questionnaires had both structured and semi-
structured questions, using 7-point Likert scale with varying responses such as not willing to 
willing or not comfortable to comfortable on a scale of 0 to 7. The demographics gathered 
included participants age, occupation, gender, current residence, and level of education 
(Appendix J). 
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How to scale and score G6PD RDT  
           Field-tested G6PD status was based on a-Yes or a-No result depending on color change 
(Yes/deficient: white color, or No/normal: purple color (Appendix: Figure 2). However, 
quantitative test was used as a reference to classify volunteers as having a normal or deficient 
G6PD status based on the lab values (Appendix J). 
1) Performance was assessed by: 
 
i) % of tests interpreted correctly by HCWs/VMWs (RDT colour result meaning deficient 
or normal) 
ii) % of CareStart™ correctly interpreted (against trained study staff and quantitative test) 
2) Feasibility of G6PD RDT use by HCW/VMWs and assess their response to administer 
hypothetical PQ by: 
a. % of HCW/VMWs stating they would be willing to prescribe/ or give PQ based 
on the RDT result and based on the counselling information provided (Not willing 
=1, willing = 7). The respondents were also given the option to comment if they 
answered “If yes” …, how likely) (Appendix J). 
3) Acceptability to testing for G6PD and willingness to give PQ questionnaires were based on a 
7-point Likert scale. The questionnaires consisted of a total of 10 Likert- scale questions. The 
scales assessed: 
a) % of HCW/VMWs willing to use G6PD RDT as a routine component of malaria case 
management. Also measured by responding (Not-comfortable =1 to Comfortable =7 with 
using RDTs). 
           The questionnaires consisted of 25 structured questions that assessed trainee knowledge on 
G6PD, CareStart™ and PQ. Each correct answer received one score. The HCW/VMW pre-training 
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questions were a total of 44 questions and Post-training questions were a total of 42 questions, 
excluding demographics.  
Training and testing for G6PD  
          HCW/VMWs. A 2-day training was held in Khmer language using “Teaching Manual 
PowerPoint” that was developed for this project. The class consisted of 104 trainees 
(HCW/VMWs), but only 94 completed the study. The first day consisted of theoretical training 
that covered the topics on G6PD deficiency, CareStartTM G6PD RDT, PQ associated risks and 
benefits, and how to recognize side effect. The teaching manual also covered the current treatment 
guidelines for malaria in the country.  PQ Counseling script (Appendix M) was reviewed with the 
trainees to aid them in effective counseling of G6PD test volunteers.  
          Following the theoretical training, a practical hands-on workshop was conducted using 
CareStart G6PD RDT on 2nd day of workshop (Appendix N). To accurately evaluate the results, 
control samples of known G6PD activity (normal and deficient samples) were purchased from 
ACCESSBIO (the maker of CareStart™) for use during the hands-on training sessions. The 
overall goal of the 2- day training and subsequent follow-up was to ensure HCW/VMWs could 
reliably screen the volunteers and effectively counsel them based on their G6PD results, and 
make hypothetical treatment recommendations based on the national treatment guidelines 
(Appendix O).  
          After the 2-days of training, each HCW/VMW was assigned a total of 16 G6PD files 
to use in field. Each trainee was assigned an expert observer (who is trained study staff) to evaluate 
their procedures in the field setting. A Checklist was used to ensure that accurate steps were carried 
out, plus accurate recording of results; and that questions regarding hypothetical dosing of PQ 
were answered. CareStart performance was assessed in the hands of HCWs/VMWs, and results 
20 
G6PD CARESTART™ RAPID DIAGNOSTIC TESTING             
 
compared against the expert readers(observers) in the field vs expert in lab using RDT, then all the 
three tests were compared against the quantitative lab test (Pointe Scientific, Inc.) which is the 
current gold standard “quantitative” method of G6PD screening in the laboratory.   
         However, the volunteers were not informed of the G6PD RDT results even if the results 
indicated deficiency until all the quantitative tests were done as a “gold standard” to confirm the 
results. At the end of the study, every G6PD volunteer who had consented to knowing their 
G6PD status was informed of their status by a designated study team member.  
          Trainees also answered a set of questions, using pre and post-training questionnaires. The 
pre-training questionnaires consisted of 44 semi-structured questions but only 25 knowledge 
questions were scored for knowledge assessment.  The other questions were 7-point Likert scale 
that assessed participant’s perception of their willingness to prescribe/give PQ or to test the 
G6PD status of patients coming to the health centers with malaria. The post-training 
questionnaire consisted of 42 questions; the same 25 knowledge questions were scored post 
training to assess if HCW/VMWs retained the information given during training. This was 
assessed at 2-days post training, and at two, four, six and eight weeks. The study staff probed 
HCW/VMWs understanding of each major topic area covered on G6PD and PQ. A checklist was 
used. Trainees who failed to receive 100% understanding on any given topic received additional 
instruction on the specific topic missed. HCW/VMW underwent this process and repeat 
counseling script training until they were able to mark “yes” to every queried section of the 
counseling DCF (Appendix N). 
Blinding 
          HCW/VMWs were blinded to the (expert’s) trained study staff’s G6PD test results until 
both results were recorded and locked to avoid untoward bias. The Trained study staff performed 
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the test first then observed HCW/VMWs do the test. However, both HCW/VMW and observer 
were blinded to the quantitative results until RDT results were “locked” in the Data Collection 
form. 
Blood sample collection  
            Currently, CareStart™ is the only “field friendly” test available for field G6PD testing. It 
is also less temperature sensitive than other qualitative G6PD tests. Enzyme activity is shown 
through a visual dye colorization, (white = deficient; purple = normal), but is limited by the lack 
of a built in control signal. The CareStart™ does not require refrigeration with recommended 
storage temperature of 18-32°C. 
         Process of Sample Collection. The blood samples for G6PD RDT testing in the field was 
collected via finger prick, the CBC and G6PD testing in the laboratory were performed on venous 
blood samples. All sample collections were performed under sterile technique. For field test using 
RDT kit, 2µl blood was pipetted from a finger prick, [ and from EDTA vacutainers in lab]. The 
pipetted drop of blood was added to the sample well using the pipette provided. Then, two drops 
of buffer supplied by the manufacturer was added to the buffer well. The results were then read in 
10 minutes according to the manufacturer’s guidelines. HCW/VMWs carried out all the procedural 
steps for testing for G6PDd, but the trained study staff performed blood test first, and 
HCW/VMWs’ then performed second. In addition, a 2 ml venipuncture blood sample was obtained 
from each ‘patient’ in Vacutainer tubes (BD Vacutainer, Franklin Lakes, NJ) containing EDTA 
(K2 Ethylenediaminetetraacetic acid) as an anticoagulant, for CBC, lab RDT and quantitative 
G6PD testing (Von Fricken et al. 2014; Gonzalo et al. 2013).  RDTs from the same batch were 
used for all participants. All field participants were blinded to the results from the 
spectrophotometric analysis (quantitative test). 
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Data Collection 
         Data collected were recorded in data collection forms (DCF) and transferred to the electronic 
database, which was password protected. Demographic data was gathered using study developed 
questionnaires. The study collected data consisted of:   
a. Questionnaires to assess acceptability of PQ treatment and effectiveness of training, 
completed by HCW and VMW; and willingness to test G6PD status of patients with 
malaria, and knowledge assessment. 
b. CareStart™ G6PD test results (RDT) from the field and quantitative lab results from a 
reference laboratory (G6PD, CBC)  
                                    Validity and Reliability of Instrument 
          HCW/VMWs evaluation. Post training, each HCW/VMW performed four to six G6PD 
RDTs using known control samples (deficient and normal). Trainees were observed by an expert 
reader (trained study staff) during the workshop training held over a 2-day period. Subsequent to 
workshop training, HCW and VMWs performed G6PD RDT test in the field setting where they 
were also observed by trained study staff to ensure correct reading of results. 
           Reference Standard. The G6PD spectrophotometric quantitative analysis used Pointe 
Scientific, Inc. (MI, USA) G6PD reagent kit. Samples collected were analysed within 24hours. 
G6PD activity was calculated and reported using the international units, corrected for haemoglobin 
levels (Appendix L). 
          Acceptability survey. At the end of each field day, to help explore trainee’ knowledge and 
understanding of G6PD and PQ, HCW/VMW completed questionnaires regarding their 
willingness to use the G6PD RDT routinely and acceptability to prescribe/give PQ, and also their 
understanding of PQ risks (Appendix J). 
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Data analysis 
            The analyzed data was retrieved from case report forms (CRF) developed for this study. 
This raw data was then entered into the electronic database, and transcribed to excel spreadsheet 
for analysis and reporting using STATA 15 program, SPSS and Graphpad Prism 7. p-values 
<0.05 indicated statistically significant differences. Sensitivity, specificity, PPV and NPVs for 
RDTs in the field and lab setting were calculated against the population adjusted median of 30% 
on reference quantitative test. Descriptive and inferential statistics were also used to analyze data 
collected. Data was downloaded directly into SPSS once it was recorded for final analysis. Test 
performance at the field was compared between samples collected from the finger prick and from 
venous samples analyzed in the lab.  
           The experts assessed trainees’ (HCW/VMW) level of understanding about G6PD RDTs 
and PQ, which was indicated by the percentage of accurately performed and correctly interpreted 
tests.  Any missing data was assumed as failed result. Lost to follow-up was low based on single 
visits required for the G6PD test volunteers and the trainees worked from their usual working 
stations.   
           Data Dissemination. The results of this study will be presented to CNM and AFRIMS. In 
addition, key findings will be presented to key country stakeholders, during AFRIMS sponsored 
workshop.  
Ethical Considerations 
           The study received approval by the National Ethics Committee for Health Research of the 
Ministry of Health of Cambodia and WRAIR IRB.  In addition, the protocol was submitted for 
review by The George Washington University IRB (GW) to assure compliance with any GW 
institutional policies.  We submitted all amendments for review and approval by all institutional 
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review boards. There were no unanticipated problems involving risks to volunteers or others, and 
no significant deviations.  Informed consent was obtained from the volunteers before inclusion in 
the study and before any study procedures. The participants’ records were kept confidential with 
limited access to records by study staff only. G6PD volunteer participants were informed of their 
G6PD status based on agreeing to receive results signed on the consent form. Result received were 
based on the gold-standard quantitative test results.             
Results  
         From December 2017 to February 2018, 94 trainees completed the 2-day training 
workshop, including 21HC staff and 68 VMWs. In this eight-week period, 960 adult male 
volunteers were assessed for G6PD deficiency. The median age of the trainees was 37 years, 
with a range of 18 to 69 years old (Appendix Q).   
I. Knowledge Assessment and Acceptability Survey 
           Trainee knowledge about G6PD and PQ was assessed based on their professional titles, 
educational levels and years of experience at their current position. At baseline, nurses had the 
highest knowledge score of 56%, but all the trainees showed improvement in their knowledge 
scores from pre- to post- training, with statistical significance in results post training (p<0.001).   
Table 1. Knowledge score: Pre and Post-training based on trainee background 
 Pre-Training % 
mean score of 
each profession 
Post-Training 
% mean score of 
each profession 
Statistics, p 
value 
 
Trainee profession    
 VMWs (n=68) 34% 88.71%  
 Nurses (n=21) 56.4% 90.0%  
 Other HC workers (n=5) 34% 96%  
TOTAL (t, p-value)   t=16.6 
 p <0.001 
Trainee level of Education    
 College graduates 53% 95%  
 High school graduates 48.9 92.4  
 Primary  33% 89.8%  
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 Secondary 38% 84.4%  
TOTAL (t, p-value)   t= 16.30, p 
<0.001 
 
Years in Experience % mean pre-
training 
% mean post-
training 
 
< 1 year 38% 91.33%  
1- < 3 years 37.5% 89.5%  
3- < 5 years 41% 78.67%  
>=5 years 37.33% 91. %2  
Total (t, p-value)   t= 16.30, p< 
0.001 
 
           Pre-training, knowledge scores based on education level indicated that college graduates 
had the leading percentage mean score of 53% with primary-level educated volunteers scoring 
33%. Post-training, college graduates had mean score of 95%, volunteers with secondary school 
education scored at 84.4%, and primary level scoring 89.8%, which was not statistically 
significant between the groups. VMWs with primary school level education, and 1 to 3 years of 
experience, scored the highest (p=0.38).  Post training, scores for willingness to test for G6PD 
deficiency, and comfort in prescribing PQ for Pf and P.v significantly improved. In relation to 
years of experience, there were no statistical differences in the mean knowledge scores based on 
profession (p=0.57) and education level (p=0.38).    
Table 2. Willingness to perform the test and level of comfort in giving treatments 
 Pre-Training Post-Training 
Willingness to test for G6PD when a patient is 
diagnosed with malaria 
56.3% (53/94) 80.8% (76/94) 
Level of comfort in giving PQ based on G6PD RDT 
results 
39.3% (37/94) 72.3% (68/94) 
Level of comfort in giving PQ to a patient with P.v 
and normal G6PD test 
36.1% (34/94) 80.0% (76/94) 
Willingness to give a patient  PQ single dose for P.f 
without G6PD screening 
20.2% (19/94) 84% (79/94) 
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II. CareStart G6PD RDT Results 
          Calculating the G6PDd <30% cut-off of adjusted male median: 1,127 adult males with 
at least 18 years of age were included in analysis. The G6PD median value (IQR) was 8.30 (7.11, 
9.61).  Mean (SD) of G6PD activities was 7.72 ( 3.35 U/g Hb.  Nineteen males who had 
G6PD quantitative value equal or less than 10% (0.83 U/g Hb) were exclude in order to calculate 
“adjusted G6PD male median value”. Adjusted G6PD male median value (IQR) was then 
estimated from 1,108 volunteers was 8.35 (7.22, 9.655). G6PDd was defined as <30% of 
adjusted male median value which is <2.51” U/g Hb. The distribution of G6PD enzymatic 
activity of our sampling population according to lab spectrophotometry ranged from 0.05 to 
22.57. Sensitivity was described as the probability that the RDT test classified an individual as 
G6PDd, who is also classified as deficient by the quantitative assay; detecting <30% of 
enzymatic activity (<2.51U/g). Specificity was described as RDT results concurring with lab 
results as G6PD normal (>2.51U/g). 
            CareStart G6PD RDT Results. We used IBM SPSS to analyze G6PD RDT test results. 
Of the 960 volunteers, 156 (16%, 95% CI 14-18) were G6PD deficient based on a quantitative 
test activity threshold of 30%. The results of field-tested CareStart™ were compared with the 
spectrophotometric methods in the laboratory at the threshold of 30% adjusted male median 
activity. There was no statistical difference in test sensitivity, specificity, PPV and NPV for 
CareStartTM at the field site (96.53%, 95.69%, 80.81%, 99.32%) compared to the results by the 
expert in the same field conditions (95.86%, 97.40%, 87.42%, and 99.21%), and 93.79%, 
98.96%, 94.44%, 98.83% for experienced laboratory study staff, with no statistical difference 
among the groups. HCW/VMWs classified 35/960 (3.64%) volunteers incorrectly as being 
G6PDd (when they were G6PD normal), compared to 20/960 (2.08%) expert in the field, and 8 
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(0.8%) by the expert in the lab.  HCW/VMWs missed to identify 5/960 G6PDd volunteers, 
compared to 6/960 misclassifications by the experts in the field, and 9/960 by the expert in the 
laboratory (Appendix P).  
Discussion  
           This is the first study that has evaluated CareStartTM G6PD RDT test in the field settings 
in Cambodia in the hands of village malaria workers and other health care workers, who were 
mostly nurses working at health centers. This is also the first report of the established normal 
G6PD activity levels based on Point Scientific Quantitative Test, which is currently the 
recommended reference test following discontinuation of the Trinity kits from production. No 
prior studies evaluated community perception on PQ, G6PD screening, and provider comfort 
with prescribing PQ based on RDT results using CarestartTM, the only point-of-care testing 
available. The training also allowed us to assess how the perceptions about PQ risk and 
limitations of G6PD screening can change, which is important in rolling out radical cure 
treatment for P.v in Cambodia.   
The results of the study showed that trainees showed much higher willingness to screen 
patients for G6PD deficiency following the 2-day workshop training likely due to increased 
understanding of the benefits and risks of PQ. CareStart G6PD RDT offered at point-of-care 
testing performed reasonably well even at the peripheral level of care, at the community level by 
village malaria workers. Making this test available at this level could increase access to testing 
and radical cure treatment.  However, it remains to be seen if VMWs can be given this new 
responsibility to screen patients for G6PD deficiency and prescribe PQ which is not without 
risks.  Based on our results, the tendency of trainees was to over diagnose G6PD deficiency, 
28 
G6PD CARESTART™ RAPID DIAGNOSTIC TESTING             
 
which explains the lower PPV.  However, no group was free from missing the diagnosis of 
G6PD deficiency.   
  The implication of this is important for the policy makers as PQ deployment will not be 
without risks, even with G6PD screening.  It is possible that new generation tests for G6PD 
deficiency could become more reliable, but this is yet to be demonstrated in the field trials for the 
next generation G6PD kits that are in development. CareStart RDT is currently the only point-of-
care test that is available commercially and that can provide an inexpensive way to test male 
patients for G6PD deficiency with little time required to make trainees proficient in interpreting 
the test results.  
           Kim et al. (2011) study indicated that CareStart had 90% sensitivity with a NPV of 98.2% 
in the controlled laboratory settings. Our study showed higher sensitivity and better NPV of 
99.29, likely reflective of the training provided, which was effective across all education levels 
and years of experience. Given the acceptable level of performance in the field settings even 
among novice users post training, it makes the results widely applicable for implementation in 
this malaria endemic areas. Implementation of the CareStart kit may be feasible at the 
community level, with limited training required and with added benefit of the low cost of 
CareStart in comparison to the quantitative tests that can only be done in temperature controlled 
laboratories.   
Study Limitations 
Wide applicability of our findings should be taken with caution when similar approaches 
are considered for implementation in other countries.  Some of the trainees had difficulty with 
reading the digital clocks, which is required to indicate the reading of results at10 minutes mark.  
This resulted in the switch from digital clocks to using timers, with audible sound at the 10 mins 
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mark.  The smaller size timers were difficult to set and were later replaced by another brand of 
the timers. These details in implementation should not be overlooked.   
In regards to pre- and post- training questionnaires, some HCWs/VMWs stated that it was 
too long and therefore, took long to complete. They also stated that despite the fact that the 
questionnaires were translated into the local language (Khmer), some of the questions were still 
reported as “technical” and required explanation by the (experts)study staff, which could have 
introduced some degree of bias in the results. The trainees also provided us with feedback that 
the pictures in the counseling script were more helpful than reading of the script to the G6PD test 
volunteers. Most trainees and G6PD test volunteers found the pictures and explanations of the 
pictures sufficient for understanding the concepts, and a better method for them to learn as 
opposed to reading the whole script.  One limitation to using CareStart™ was lack of the control 
line, which was previously recognized as a significant limitation from prior studies in the lab 
setting.  In this case, supervision of testing will be beneficial, possibly in the form of re-training 
to make sure that trainees read the tests correctly, follow proper procedures, and record the 
results within the specified time of 10 minutes; otherwise, delayed reading can result in wrongful 
interpretation of the results.  
Implications for practice, policy and research 
        The outcomes from this study show that with limited training, novice users can become 
quite proficient at reading and interpreting CareStartTM RDT results.  This test is only suitable for 
use in male patients.  However, with males being the predominant population affected by malaria 
in Cambodia, deployment of this test can increase access to radical curative doses of PQ. 
Increasing access to G6PD screening will allow more patients to be cured from P.v and this can 
help with prompt implementation of malaria elimination goals that have been set to eliminate P.v 
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in Cambodia by 2025 (MESA, 2016).  The piloted G6PD counseling tools were highly effective 
and could be modified and adopted for wider use in clinical practice in Cambodia.   
Conclusions 
           CareStart RDT shows promising results in terms of test sensitivity and ruling out G6PD 
deficiency. This study indicated that point-of-care screening for G6PD deficiency at the 
community level is feasible. However, incorrect interpretation of a few G6PD RDT test results 
will occur, and monitoring must be put in place before deployment of PQ treatment in 
Cambodia. Willingness of patients to be treated with PQ despite risks will likely result in lower 
cases of P.v malaria recurrence, and malaria morbidity from frequent P.v relapses in Cambodia. 
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Appendix A: Current Map of Malarial Incidence in Cambodia 
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Appendix B: Training Manual (English, also translated to Khmer). 
PowerPoint Slide that covered several Objectives  
 Provided a rationale for recommending treatment with Primaquine 
 Educated on risks and benefits of Primaquine treatment following G6PD deficiency 
screening 
 Reviewed recommendations on who needs G6PD screening 
 Provided training on the correct use and interpretation of RDTs for G6PD deficiency 
screening 
 Provided an overview of the current limitations of available point-of-care testing for 
G6PD deficiency 
 Trained healthcare workers using a formulated “Counseling Script” on Primaquine 
and G6PD screening 
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Appendix C: Communication planning model developed by NIH and CDC (RBM, 2012) 
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Appendix D: Variable Table with Theoretical and Operational Definitions  
 
Variable Theoretical Definition Operational Definition 
 
Demographics 
Gender Patient’s biological sex 1=Male 2=Female 
Age Chronological age in years Years of age as defined 
as current date minus 
birth date. Defined as:  
1=18-<30, 2=30-<45, 
3=45-<60, 4=>60 
Race Biological or genetic traits 
based on various sets of 
physical characteristics 
1=Caucasian 
2=Black 
3=Hispanic 
4=Asian 
5=other 
 
Educational level Level of educational level 
completed 
1=Grade school 
2=High school 
3=College 
4=Graduate school 
 
Dependent 
Primaquine 1 Recommended as part of 
treatment for P.vivax (radical 
cure course) 
Yes=1 No=2 
Primaquine 2 Recommended as part of 
treatment to block malaria 
transmission (single dose) 
Yes=1 No=2 
Perception of threat Based on demographics and 
recent history of malaria 
Is patient G6PD deficient 
Yes=1 No=2 
Susceptibility to malaria Based on demographics and 
recent history of malaria  
Yes=1 No=2 
RDT G6PD test results Concordance of RDT results 
by VMWs and trained study 
staff 
Yes=1 No=2 
Effective counseling of PQ 
safety 
Effective communication on 
PQ safety, as assessed by 
volunteers level of 
understanding of risks and 
benefits  
1=Volunteers not able to 
clearly state side effects 
of PQ or signs or 
symptoms of hemolysis 
2=Volunteer able to cite 
one symptom of 
hemolysis but reports 
lack of understanding 
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when to seek medical 
career 
3=Volunteers reports 
understanding of the side 
effect profile of PQ, can 
state when he/she needs 
to seek medical care, and 
can recite clearly most 
signs and symptoms of 
hemolysis 
Healthcare training Effective teach-back  Yes=1 
No=2 
Independent 
Level of education/literacy Education level of trainee 1=less than 12th grade 
2=12 grade or higher 
3=Literate (able to write 
and read) 
4=Not able to write or 
read Khmer  
5=VMW 
6=Nurse 
7=Physician 
Training module Type of training received 
and teach-back 
1=hands-on training with 
the use of RDTs only 
2=attended 
comprehensive training 
workshop 
3=Video training 
Malaria P. vivax control 
and prevention practices 
Healthcare staff education 
(nurses, medics, malaria 
village workers) and patients 
are counselled on malaria 
management 
 
Have mosquito nets 
Yes=1 No =2 
Tested for malaria/G6PD 
deficiency 
Yes=1 No =2 
RDT testing G6PD screening with RDTs 2=Storage conditions 
3=Equipment and 
reagents used correctly  
4=Time to results 
5=Interpretation of 
results 
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Appendix F: Study Information-Community Announcement 
 
 
 
 
 
 
 
 
 
42 
G6PD CARESTART™ RAPID DIAGNOSTIC TESTING             
 
Appendix G: Informed Consent Form (Translated to Khmer) 
I. STUDY INFORMATION AND INFORMED CONSENT FORM  
(Trainee volunteers)  
PROTOCOL TITLE: Evaluation of the CareStart™ glucose-6-phosphate dehydrogenase 
(G6PD) rapid diagnostic test at community and health center level, Cambodia 
INTRODUCTION  
You are being asked to participate in a research study entitled “Evaluation of the CareStartTM 
glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test at community and health 
center level, Cambodia”. In this study, you will be trained to use a new kind of rapid diagnostic 
test (RDT), called CareStartTM, a test that is similar to a malaria rapid diagnostic tests. The test 
requires a finger prick to collect a small amount of blood from volunteers who desire testing in 
order to determine the G6PD activity (normal or reduced) in their blood. Since the testing for 
G6PD deficiency is being recommended by national malaria program, in order to provide 
antimalarial drug Primaquine safely, we need to identify suitable tests that are easy to use and 
can be used in the field settings. Screening of patients for G6PD deficiency is needed in order to 
minimize the risks from taking Primaquine. So far CareStartTM has been used successfully only 
in special settings, like a lab or hospital. It is hoped that this research will give us better 
information about how well the test works when used at a health center or at the village level 
when the test is performed by a village malaria worker (VMW) or by military medics. We hope 
this research will assist the Cambodia Ministry of Health in determining if G6PD testing can be 
done properly at the community level. This study will help establish the appropriate level of care 
delivery where this test can be performed successfully following appropriate training. 
 
43 
G6PD CARESTART™ RAPID DIAGNOSTIC TESTING             
 
STUDY DESCRIPTION Your participation will involve taking part in the 2-day training 
workshop focusing on testing for G6PD deficiency, use of Primaquine for malaria treatment and 
how to conduct the G6PD screening with RDTs. We anticipate that approximately 104 VMWs 
and other health workers will participate in this study. We will conduct training in smaller groups 
to facilitate learning environment. Following the workshop training, you will be observed 
conducting the G6PD screening tests on patient volunteers in your usual place of work. Each 
trainee will test approximately 16 volunteers during the course of study participation, for 
anticipated total of 1,600 patient volunteers tested by all trainees who participate in this study. 
Each trainee will also be asked to complete pre- and post- training questionnaires to help us 
understand current knowledge gaps about the drug Primaquine and about G6PD screening, and 
the willingness and acceptability of trainees to use Primaquine and G6PD screening tests in their 
place of work. The feedback we get from this study will help us optimize training materials for 
healthcare staff who may use Primaquine or G6PD screening tests. Based on the test 
performance, we will also be able to assess if the available G6PD screening tests (such as 
CareStartTM) are appropriate tests for use in the field settings. 
Who is eligible to participate? You have been asked to participate because you are a village 
malaria worker or health center staff or medic who manages malaria patients, and work within 
the study location. You should seek permission from your supervisor before you participate in 
the study. You can participate in this study if: • You are employed as village malaria worker or 
healthcare staff likely to diagnose and/or treat patients with malaria (nurses, medics, physicians 
are eligible) • You are able to participate in the 2-days workshop training • You agree to a 
minimum of 4 days of G6PD screening/testing of volunteers • You have no plans to move 
outside study area over the course of next 3 months You cannot participate in this study if: • You 
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have known color blindness • Judged by the investigator to be unsuitable for study participation 
In order for you to be enrolled in the study, you will also have to sign the consent form stating 
your willingness to participate. 
What if I do not want to take part in this study? Participation in this study is strictly 
voluntary. If you decide not to participate in this study, you will NOT lose any medical or other 
benefits for you or your family. If you do not participate in this study, this will not have any 
negative effect on your ability to continue working at your current place of work. 
How long will this study last: Your participation will last approximately 3 months. This 
includes the 2 days’ workshop training and the time needed to recruit sufficient number of 
volunteers who will be tested by you for G6PD deficiency. You will be asked to test 
approximately 4-8 patient volunteers in one day, for a total of approximately 16 volunteers, 
during your study participation. So your active participation is expected to be approximately 6 
days (2 days for workshop and 4 days for screening of patients – 4 volunteers per day), spread 
over the three-month period. These timelines can be adjusted if recruitment is slower than 
anticipated. You should also know that the test takes approximately 10 minutes to complete, per 
patient. However, you will also be asked to complete pre- and post-training questionnaires, and 
may be asked to participate in a group discussion, which will require additional time. However, 
your time participation on any given day will not exceed 8 hrs. 
Study Procedures After enrollment you will be asked to provide information about your prior 
experience with malaria treatment and asked questions to assess your current knowledge about 
Primaquine and G6PD screening tests (pre-training questionnaire). Then you will receive 
training on G6PD, screening tests, and Primaquine. Training will also include hands-on 
workshop on how to use CareStartTM. After training you will be evaluated using G6PD RDTs 
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and you will be asked to answer a few questions about the training and training materials. If 
needed, you will receive re-training before going out to check volunteer patients’ G6PD status 
using the RDTs at your village. 
Check volunteer patients’ G6PD status Within a few days of completing the training, you will 
be observed conducting the test on patient volunteers in your usual place of work. You will 
conduct the test on 4-8 patients per day to complete approximately 16 G6PD screening tests 
during this study. The total number of patients screened may differ slightly between trainees 
based on the recruitment of volunteers at each village. If you screen 4 patients a day, it will take 
4 days to reach the target of 16. You will also be asked to collect details on patient’s age, sex, 
level of education, and contact information for follow-up visit. Then you will be asked to 
complete additional post questionnaires about G6PD screening, Primaquine, and RDTs During 
your study participation you may be asked to participate in group discussions so we can better 
understand current knowledge gaps and the responses in the questionnaires. 
Blood Tests During the Study As part of the study, you (trainee) will be asked to do a finger 
prick (1 or 2 drops of blood) on another trainee, during the workshop training. This means that 
during the workshop training, another trainee may practice finger prick on you as well. 
Following the training, you will be asked to do a finger prick to check volunteer patients’ G6PD 
status using the RDT, during the observation visits by study team. Separate to the finger prick, a 
study team member will collect additional blood (approximately 2 ml) from the patient volunteer 
and send it for testing at a lab close to the treatment facility for confirmatory G6PD screening 
(for comparison of test results to those with RDTs). 
Optional You will NOT be photographed and/or videotaped unless you provide us with consent 
allowing us to do so. This part is optional and not required to be able to take part in this study but 
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this can be helpful to us in development of future training and education materials. 
NOTE: There will be NO photos or videos taken on military installations at any 
time. 
STOPPING THE STUDY The entire study or a part of the study may be stopped at any time 
based on the judgement of the study researchers, the study sponsors, or the ethical committees. 
POTENTIAL RISKS Taking blood from your finger during training will cause a brief sharp 
pain. The pain is usually mild, and can be described as pinching or pricking your skin with a 
sharp object only when we try to collect the blood. This discomfort lasts only a short time, 
usually less than 1 minute. All standard precautions will be taken to reduce any potential risk 
from accidental exposures to infected blood during finger prick procedure. This risk will be 
mitigated by requiring that all trainees wear surgical gloves when performing the finger prick on 
volunteers and this will be strictly enforced.  
ANTICIPATED BENEFITS There are no other direct benefits to you from participating in this 
study other than potentially increasing your medical knowledge. The information from this study 
may help other people in the future who have malaria, a disease the kills more than 400,000 
people worldwide every year. The study will benefit the community as a whole by providing up-
to-date information on G6PD diagnosis and malaria treatment which will be provided to the 
National Malaria Control program, and other appropriate Cambodian government authorities. 
SUBJECT RIGHTS Your participation in this study is voluntary. You may withdraw from the 
study at any time without penalty. You must inform the researcher of this decision as soon as 
possible. Deciding to leave the study will not influence the availability of future medical care or 
other benefits to which you are otherwise entitled. You are not waiving any legal rights by 
participating in this study. If you have any questions concerning the study, you may contact Dr. 
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Chanthap Lon, Armed Forces Research Institute of Medical Sciences (AFRIMS), No. 5 St. 550, 
Phnom Penh, Cambodia. Tel.: +855 12 976 799. 
OR 
Study team contact number 097 9484 597 or 097 9484 598 If you have any questions about 
your rights as a research participant in Cambodia or wish to speak to a person not associated with 
this research, you may contact: Dr. Vonthanak Saphonn, Secretary of the Nation Ethics 
Committee Health Research IRB#1(NECHR: IRB# 3143) #2 Kim Il Sung Blvd, Khan Tuol Kok, 
Phnom Penh. Cambodia, Tel.: 023 880 345, Fax: 023 880 346, E-mail: research03@nchads.org. 
The results of this study will be published in scientific journals and the data will be made 
available to health care officials in Cambodia, but there will be no specific effort to inform you 
of the results of this study. Your name or other identifying information about you will not be 
made publicly available except for those trainees who consented to be photographed or 
videotaped. 
MEDICAL CARE FOR RESEARCH RELATED INJURY If you are injured as a direct 
result of your participation in this study, you should inform study team immediately. You will 
receive medical care for that injury at the appropriate local medical facility, following current 
standard of care, at no cost. The sponsor of this study is responsible for the medical costs. This 
medical care provision does not constitute a waiver or release of your legal rights. You will not 
receive additional compensation for this injury. If you have questions about this medical care, 
talk to the Principal Investigator for this study. 
COMPENSATION For VMWs, HC staff, and/or medics the compensation will be 56,000 
Cambodian Riel (approximately US $14/day) for each day of training (2 full days) and the same 
amount (~$14) on the days they are screening volunteers for G6PD deficiency (estimated as 4 
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days for each trainee). If the trainee requires more than 4 days to 
screen 16 volunteers, the compensation on days of screening will be limited to 
4 days only. The compensation for VMWs/HC staff and medics who will screen volunteers for 
G6PD deficiency, takes into consideration the government set local per diem rates that is 
approximately $14/day. Compensation for all volunteers also takes into consideration lost 
earnings, meals and incidentals arising from participation. 
CONFIDENTIALITY Your research record and personal information such as name, address, 
date of birth, etc., will be kept confidential and will not be made available to individuals or 
organizations who are not involved with the study, unless required by applicable law. If the 
results of this study are published in the medical literature, your identity will not be revealed. By 
signing this consent form, you are granting permission for your medical records collected under 
this study, to be reviewed by the study staff, authorized representatives of ethical committees 
who have approved this research, other regulatory authorities reviewing this study, and the study 
Sponsor’s representatives. All of these are responsible to ensure that the research is conducted in 
an ethical, safe, and legal manner to protect your rights and your safety. Your record includes 
participation date, study code, name, age, sex, contact address and the reason if you cannot 
participate in the study will be kept in a secure location by the investigators for 5 years at 
AFRIMS office in Cambodia once the study is completed. The study data may be entered into an 
electronic database, which will be password protected. The review of these medical records may 
be in respect to this study and any further research that may be conducted in relation to it. Your 
records may be reviewed, as described above, even if you withdraw from the study. For military 
volunteers (medics), complete confidentiality cannot be guaranteed because information bearing 
on a soldier’s health may be required to be reported to appropriate medical or command 
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authorities. However, this risk is mitigated as no highly sensitive information is being asked of 
the volunteers except general question about overall health status. 
CERTIFICATES OF CONSENT I, the undersigned, have read, or have had read to me 
in language understandable to me, the above information. Before signing this consent form, a 
member of the research team has explained to me in detail, and I understand, the objectives, 
procedures, and risks possibly associated with this study as well as the benefits. The research 
team has answered all my questions willingly, clearly, without concealment and to my 
satisfaction. I have a right to withdraw from the study at any time. My participation in this 
research is voluntary. I can choose not to participate. Refusal or discontinuation of my 
participation will involve no penalty or affect the standard care that I would otherwise expect to 
receive. If I join this project, I can ask the researcher or his representative at any time about the 
project. I will be provided with a copy of this consent form. I understand that I can choose to be 
photographed and/or videotaped during this study. If refused, I can still take part in the study. 
The research team has confirmed to keep any data concerning myself confidential and my name 
and identity will not be revealed in any reports. Only authorities involving in the support or 
monitoring of this project may be permitted to examine my data. I consent of free will for the 
following (check one): 
All required procedures to include permission to be photographed and/or videotaped 
All study procedures WITHOUT being photographed and/or videotaped 
________________________ 
__________ ______________________ 
Signature of the volunteer Date Print name I have explained the purpose of this study to the volunteer 
and have answered all of the questions. ________________________ 
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__________ ______________________ 
Signature of person obtaining consent Date Print name 
WITNESS I have witnessed the accurate informed consent process to the volunteer, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely. _______________________ 
__________ _________________________ 
Signature of the witness /ombudsman Date Print name 
Copy provided to the participant _____________ (initials of person obtaining consent) 
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APPENDIX H: Training Steps 
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Appendix I: Supervisor Permission Approval form (Khmer). 
 
Translated from English Supervisor Approval Form-Trainee: version 13 October 2017  
                      កាអនញុ ្តរបសអ់នកគ្ប់គ្ង 
ខ្ញុំង់ចូលរួមក្ងងឿរសិក្ា ន ងាា ែាលមាចុុំងន ងា ងថ “ កាវាតម្ៃាលងល លតស្សហ័ស្ាសី្ា ាភិីឌី 
( G 6PD)មស្ា្ ា ់ស្គ្ ់ឈាស្គ្មងៅតាសគៃមៃ៍ ៃាា ងមណ្ លស្ ខភា ក ង ន ងស្គ្ ស កម ព 
ជា  ’ ។ 
ខ្ញុំ ត្ាួរពិ ាងិរើង ឿលវិភាន ត្ា រតិឿរណៃ៍សត្ា ាង់ាឿរសិក្ា  ន ងា ន ងាឿជា្ថ ងាឿរចូលរួមរបស់ខ្ញុំា ង 
មិ ងរ ំៀ ែាល់រួនាារីបស់ខ្ញុំទ។ 
ខ្ញុំ ពិ ាងិរើ ន ងា ងវិញ ាូងវឿរសិក្ា  ាងិងឿលវិភារបស់ខ្ញុំ ាួ  ា ងនមបញ្ងា ងាឿរ ែាាូងចំៀងនតម ខ្ញុំ្ាូវ 
ងាឿងរឿរអ ាុស្ញពីងារ់ែនងា ងម បីចូលរួមក្ងងឿរសិក្ា ។ 
ង  ប់ចមលងន ទតង់ន ងាា ា ងត្ាូវបាដា្នងា ក្ងឯក្ា ងាឿរសិក្ា របស់ខ្ញ ។ 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
រថនងលំៀរបស់សិឿងខ ឿម ងាឿលបរិនងចទ( d /MM/y ) 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
ន ា្ ងាា បស់សិឿងខ ឿម 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
អនកគ្បគ់្ងតាឋាា ាុគ្ម៖ 
ខ្ញុំល់ថ ងាឿរចូលរួមក្ងងឿរសិក្ា ន ងាា ា ងត្ាូងវឿរនពលនវលាបស់បុគ្គ្លិកងនងល អាមាផលប ងា 
ព់ ែាងល់ឿរអ ាុវរត ាៃ៍របស់ពួកគ 
ខ្ញុំ ាុស្ញនងល ឿរចូលរួមរបស់បុគ្គ្លិកងនងល ក្ងងឿរសិក្ា ន ងាា  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
រថនងលំៀរបស់អនក្ាបាត់ង ងាឿលបរិនងចទ 
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Appendix J: Pre-Training and Post Training questionnaires 
TRAINEE (HCWs/VMW/Medic) 
(Complete PRIOR to training) 
Visit Date: ______________________________ 
(dd/MM/yy) 
 
 
 
 
 
DEMOGRAPHICS 
 
1. Age:  _______ (Years) 
2. Sex:   Male    Female 
3. Occupation: 
 Physician    Nurse    Lab technician 
 Village Malaria Worker  Medic 
 Other________________________________________________________ 
 
4. Highest education level completed: 
 Primary School (grades 1-6)    Secondary (grades 7-9) 
 High-school (grades 10-12)    College  
 Post-graduate degree (for example PhD or MD) 
 
5. The number of years I have been working at my current position (i.e 
nurse/VMW/medic) 
 
 <1 year       1 year to <3 years 
 3 years to <5 years     5 years or more 
 
6. In what setting do you normally work? 
 Hospital 
[Please Check () or Mark (X) to select your answer; if more than one answer can be selected, it will be stated in the question; 
for all other, only ONE answer can be selected] 
 
NOTE: You are not expected to know the answers to all the questions.  If you do not know the answer, you can select, I do 
NOT KNOW.  The information you provide will help us develop future teaching materials to address the knowledge gaps.   
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 Health center/Health post 
 Community/malaria village worker 
 Military 
 
KNOWLEDGE ASSESSMENT PRIMAQUINE AND G6PD 
SCREENING  
[Please Check () or Mark (X)] 
 
7. Have you heard about drug Primaquine (PQ)? 
 Yes    No  
 
8. Do you know what Primaquine is used for? 
 Yes (specify): _________________________________________________  
 No  
   
9. Do you know of any benefits of Primaquine for people with P. vivax malaria? 
 
 Yes (specify): _________________________________________________  
 No 
 
10. Do you know of any benefits of Primaquine for people with P. falciparum malaria? 
 
 Yes (specify): _________________________________________________  
 No 
 
11. Do you know of any risks or side effects associated with taking Primaquine? 
 
 Yes (specify): _________________________________________________  
 No 
 
12. Have you ever prescribed Primaquine? 
 Yes, for what disease: ___________________________________________ 
 No 
 
13. Have you ever treated a patient with acute hemolysis or severe anemia? 
 Yes    No    
 
14. Have you heard of a condition known as Glucose-6-phosphate dehydrogenase (G6PD) 
deficiency? 
 
 Yes    No 
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15. Primaquine should NOT be used if the patient has (select all that apply): 
 Headache    Fever   Malaria 
 Mild abdominal pain   G6PD deficiency  I do not know 
 
16. When taking Primaquine, patient should be monitored for the following? (select all that 
apply): 
 Pallor      Dizziness   Yellow skin or eyes 
 New onset or worsening fatigue  Back pain   Shortness of breath 
 Change in color of your urine to dark, tea color 
 Monitoring is NOT needed   I do not know 
 
17. Per current treatment recommendations in Cambodia, who should be treated with 
Primaquine? (select all that apply): 
 Anyone with falciparum malaria (including G6PD deficient patients) 
 Anyone with falciparum malaria (MUST have G6PD normal results) 
 Anyone with vivax malaria (including G6PD deficient patients) 
 Anyone with vivax malaria (MUST have G6PD normal results) 
 I do not know 
18. What is the benefit of treatment with Primaquine? (select all that apply): 
 
 Primaquine kills the parasites that hide in the liver 
 Primaquine can lower the risk of having vivax malaria recurrence 
 Primaquine can be used for malaria treatment as monotherapy 
 I do not know 
 
19. What may happen if patient accidentally takes Primaquine when he/she is G6PD deficient? 
(select all that apply): 
 Patient may become sick from the side effects of Primaquine 
 Patient may develop weakness or sudden change in the color of the urine 
 Red blood cells that carry oxygen can get damaged 
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 Nothing will happen because Primaquine is very safe  
 I do not know 
 
20. The risk of side effects with Primaquine can be reduced with G6PD testing: 
 True    False   I do NOT know 
21. Primaquine is recommended for cure in patients with vivax malaria if they have normal 
G6PD test: 
 True    False   I do NOT know 
22. Primaquine is REQUIRED to be cured of falciparum malaria: 
 True    False   I do NOT know 
23. If a patient has falciparum malaria, they can take 1 (one) dose of Primaquine without 
checking their G6PD status. 
 True    False   I do NOT know 
24. Who should be tested for G6PD deficiency using the Rapid Diagnostic Test (i.e 
CareStartTM)? 
 Males    Females   Both males and females 
25. How will you prescribe Primaquine for adult patient with vivax malaria (G6PD 
normal)? 
 14 tablets to take in one day 
 One tablet taken every day, until patient feels better  
 1 tablet a day for 14 days to complete full 2-week course, even if all malaria symptoms 
disappear at the end of week one 
 1 tablet on the first day of treatment only 
 I do not know 
 
26. After I take Primaquine for vivax malaria, which of the following is true: 
 I can still get vivax malaria again if I get bitten by an infected mosquito in the future 
 I am permanently protected from vivax malaria after I take Primaquine 
 I do not know 
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27. Taking 1 dose (1 tablet) of Primaquine if patient has falciparum malaria helps the community 
by lowering the risk of malaria spread. 
 True   False   I do NOT know 
28. Taking 1 dose (1 tablet) of Primaquine by a patient with falciparum malaria is safe, without 
need for G6PD testing. 
 True   False   I do NOT know 
29. Taking 2 weeks course of Primaquine by a patient with vivax malaria is safe, without G6PD 
testing. 
 True   False   I do NOT know 
30. If urine suddenly becomes dark, cola-colored (shown below), the patient should: 
 
31. Pregnant women and women who are breastfeeding can take Primaquine safely. 
 True   False   I do NOT know 
32. What is the benefit of Primaquine treatment for a patient with P. falciparum?  
 No benefit, treatment is NOT recommended 
 Benefit is small  
 The community can benefit by lowering the risk of malaria transmission to 
others  
  I don’t know 
33. How beneficial is Primaquine treatment for a patient with P. vivax?  
 No benefit, treatment is NOT recommended 
 Seek medical care immediately 
 Monitor this situation over the next 3-5 
days 
 Continue taking Primaquine to make sure can be 
cured from malaria 
 I don’t know 
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 Benefit is small  
 Majority of patients can benefit from treatment (it is required for cure) 
 I don’t know 
34. How long do you have to wait before reading G6PD RDT results (CareStartTM)? 
 2 min    5 min   
 10 min    15 min 
 I don’t know 
 
35. What can affect the test performance of G6PD screening test such as CareStartTM (select all 
that apply): 
 Temperature >32 degrees 
 Novice user not familiar with the color interpretation 
 Reading of the test at 15 mins rather than 10 mins 
 I don’t know 
36. When interpreting the G6PD RDTs, the patient is G6PD deficient when: (SELECT ALL 
THAT APPLY)? 
 The color in the reading window is WHITE 
 The color in the reading window is PURPLE 
 The color in the reading window is VERY FAINT PURPLE 
 I don’t know 
 
37. A male patient has G6PD result shown below, what do you recommend next? 
    
 
 
 
38. A male patient has G6PD result shown below, would you recommend 
Primaquine? 
 
 
 
 
 
 
 Treatment with Primaquine 
 Counsel the patient that he/she is G6PD deficient 
 Repeat the test 
  I don’t know 
 
 Yes 
 No 
 I 
don’t 
know 
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39. A mother comes to the clinic and informs you that she is feeling tired and her lips look pale 
after taking her husband’s anti-malaria treatment. On inquiry, you discover he was prescribed 
Primaquine a week ago and felt better quickly, so he shared his remaining medications with 
his wife who he thought also had malaria. What is the most important step you should take at 
this time? 
 
 Prescribe additional tablets of Primaquine so the patient has enough to finish 2 weeks’ 
course 
 Discharge home with instruction to return if she develops a fever  
 Immediately refer to the nearest hospital for urgent evaluation 
 I don’t know 
 
ACCEPTABILITY OF G6PD TESTING AND PRIMAQUINE 
TREATMENT 
[Please Check () or Mark (X) to select your answer] 
G6PD TESTING 
40. How reliable is G6PD screening test for male patients (Rapid Diagnostic Test such as 
CareStartTM)? 
   Not reliable                Very Reliable  
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
41. How reliable is G6PD screening test for female patients (Rapid Diagnostic Test such as 
CareStartTM)? 
  Not reliable        Very Reliable  
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
42. G6PD screening tests should be made available at the following locations (select all that 
apply): 
 In the village, testing by Village Malaria Worker 
 Health clinic 
 Hospital  
 
43. Are you willing to test patients for G6PD deficiency every time they have malaria? 
   Yes    No    I don’t know 
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44. How comfortable are you providing Primaquine treatment based on the G6PD Rapid 
Diagnostic Tests only:  
         Not comfortable         Very comfortable 
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
45. How willing are you to use G6PD screening tests that can misclassify few patients who are 
deficient as being normal (due to limitations, some tests many give incorrect result)? 
  Not acceptable                  Acceptable 
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
46. In your view, what is the likelihood of G6PD rapid test showing wrong result? 
         Very low              Very high 
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
47. What are your thoughts about G6PD screening with RDTs? 
☐ I am supportive, reason:  
☐ I am not supportive, reason:  
☐ I am not sure 
PRIMAQUINE RISK 
48. How willing are you to give Primaquine to a patient with P. vivax malaria and normal 
G6PD test? 
 
         Not willing               Willing  
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
49. How willing are you to give Primaquine single dose treatment for P. falciparum for a patient 
NOT screened for G6PD deficiency? 
    
   Not willing                Willing 
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1 2 3 4 5 6 7 
       
 
   I don’t know 
  Comments: 
____________________________________________________________ 
50. How willing are you to give 2 week course treatment of Primaquine to MALE patients with 
vivax malaria and normal G6PD status (based on CareStartTM RDT)? 
   Not willing              Willing 
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
51. How willing are you to give 2 week course treatment with Primaquine to a FEMALE patient 
with vivax malaria and normal G6PD status (based on CareStartTM RDT)? 
   Not willing               Willing 
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
52. In your view, what is the risk of single dose treatment with Primaquine, when test shows 
you are G6PD deficient (based on CareStartTM RDT)? 
   No risk                                                                                  Very high risk 
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
53. In your view, what is the risk of single dose treatment with Primaquine, when test shows 
you are G6PD normal (based on CareStartTM RDT)? 
        No risk                                                                                  Very high risk 
1 2 3 4 5 6 7 
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   I don’t know 
54. In your view, what is the risk of 2 week course treatment with Primaquine when test shows 
you are G6PD deficient (based on CareStartTM RDT)? 
         No risk                                                                                Very high risk 
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
55. In your view, how high is the risk of 2 week course treatment with Primaquine, when test 
shows you are G6PD normal (based on CareStartTM RDT)? 
         No risk                                                                                 Very high risk 
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
56. Please select if the treatment with Primaquine results in greater risk or benefit, for the 
following scenarios: 
Malaria Primaquine  G6PD 
status 
Greater 
benefit 
Greater 
risk 
I 
don't 
know 
P.falciparum single dose 
(1 tablet) 
deficient    
P.falciparum single dose 
(1 tablet) 
normal    
P.vivax 2 week 
course  
deficient     
P.vivax 2 weeks 
course 
normal    
 
57. How confident are you in performing RDTs for G6PD screening? 
   Not confident                         Very confident 
1 2 3 4 5 6 7 
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   I don’t know 
58. How confident are you in your interpretation of the results of the G6PD screening test 
based on the color change (CareStartTM RDT kit)  
 
   Not confident               Very confident 
1 2 3 4 5 6 7 
       
 
   I don’t know 
 
59. Do you have any additional comments about Primaquine safety or G6PD testing? 
 Yes: 
_____________________________________________________________ 
 No 
 
60. Which questions did you find confusing or in your view, should be removed (list by 
number)? 
      _____________________________________________________________________ 
Completed by: _____________________ 
(Trainee) 
 
Reviewed form completeness by: _____________________ 
(Researcher or Designee) 
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TRAINEE (HCWs/VMW/Medic) 
(Complete AFTER training) 
Visit Date: ______________________________ 
(dd/MM/yy) 
 
 
REVIEW OF THE TRAINING  
1. The scope of the material and training was relevant to my job 
    Disagree                        Strongly Agree 
1 2 3 4 5 6 7 
       
 
2. The material was well organized and easy to understand 
   Disagree             Strongly Agree 
1 2 3 4 5 6 7 
       
 
3. The examples presented helped me understand the content 
   Disagree             Strongly Agree 
1 2 3 4 5 6 7 
       
      
4. The hands-on training workshop on the use of G6PD RDTs added value to my learning 
   Disagree                         Strongly Agree 
1 2 3 4 5 6 7 
       
 
 
 
 
5. The use of known G6PD controls added to my learning and I would recommend it in future 
workshops 
Please Check () or Mark (X) to select your answer; if more than one answer can be 
selected, it will be stated in the question; for all other, only ONE answer can be 
selected 
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   Disagree                        Strongly Agree 
1 2 3 4 5 6 7 
       
 
6.  What is the OPTIMAL number of known G6PD controls that should be used for practice in 
the workshop?  
 
 3 normal, 3 deficient, 3 intermediate 
  Fewer number of controls can be used for training purposes 
  Greater number of controls would be beneficial to become more familiar with the 
possible color changes  
 
7.  The use of AccessBio Reference Color Card is helpful in test interpretation of CareStartTM   
RDT 
 
   Disagree             Strongly Agree 
1 2 3 4 5 6 7 
       
 
8.  I would recommend this training to others  
         Disagree              Strongly Agree 
1 2 3 4 5 6 7 
       
 
9. The content was presented in a way that allowed for sufficient learning 
   Disagree                        Strongly Agree 
1 2 3 4 5 6 7 
       
 
 
10.  The length of training was:  
 Too long    Too short    Just about right 
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KNOWLEDGE ASSESSMENT PRIMAQUINE AND G6PD 
SCREENING  
[Please Check () or Mark (X)] 
 
11. Do you know what Primaquine is used for? 
 Yes (specify): _______________________________________________________  
 No 
 
12. Do you know of any benefits of Primaquine for people with P. vivax malaria? 
 
 Yes (specify): _______________________________________________________  
 No 
 
13. Do you know of any benefits of Primaquine for people with P. falciparum malaria? 
 
 Yes (specify): _______________________________________________________  
 No 
 
14. Do you know of any risks or side effects associated with taking Primaquine? 
 
 Yes (specify): _______________________________________________________  
 No 
 
SCORED QUESTIONS 15 TO 39 
 
15. Primaquine should NOT be used if the patient has (select all that apply): 
 Headache    Fever    Malaria 
 Mild abdominal pain   G6PD deficiency   I do not know  
  
16. When taking Primaquine, patient should be monitored for the following (select all that 
apply): 
 Pallor     Dizziness   Yellow skin or eyes 
 New onset back pain   New onset or worsening fatigue 
 Shortness of breath   Change in color of your urine to dark, cola color 
 Monitoring is NOT needed  I do not know  
 
17. Per current treatment recommendations, who should be treated with Primaquine (select all 
that apply): 
 Anyone with falciparum malaria (G6PD normal and G6PD deficient patients) 
 Anyone with falciparum malaria (MUST have G6PD normal results) 
 Anyone with vivax malaria (G6PD normal and G6PD deficient patients) 
 Anyone with vivax malaria (MUST have G6PD normal results) 
 I do not know 
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18. What is the benefit of treatment with Primaquine (select all that apply): 
 Primaquine kills the parasites that hide in the liver 
 Primaquine can lower the risk of having vivax malaria recurrence 
 Primaquine can be used for malaria treatment as monotherapy 
 I do not know 
 
19. What may happen if patient accidentally takes Primaquine when he/she is G6PD 
deficient? 
 Patient may become sick from the side effects of Primaquine 
 Patient may develop weakness or sudden change in the color of the urine 
 Red blood cells that carry oxygen can get damaged 
 Nothing will happen because Primaquine is very safe  
 I do not know 
20. The risk of side effects with Primaquine can be reduced with G6PD testing: 
 
 True    False   I do NOT know 
21. Primaquine is recommended for cure in patients with vivax malaria if they have normal 
G6PD test: 
 
 True    False   I do NOT know 
 
22. Primaquine is REQUIRED for cure from falciparum malaria: 
 
 True    False   I do NOT know 
 
23. If a patient has falciparum malaria, they can take 1 (one) dose of Primaquine without 
checking their G6PD status. 
 
 True    False   I do NOT know 
 
24. Who should be tested for G6PD deficiency using the Rapid Diagnostic Test? (i.e 
CareStartTM): 
 
 Males    Females   Both males and females 
 
25. How will you prescribe Primaquine for adult patient with vivax malaria (G6PD 
normal): 
 14 tablets to take in one day 
 One tablet taken every day, until patient feels better  
 1 tablet a day for 14 days to complete full 2-week course, even if all malaria symptoms 
disappear at the end of week one 
 1 tablet on the first day of treatment only 
 I do not know 
 
26. After I take Primaquine for vivax malaria, which of the following is true: 
 I can still get vivax malaria again if I get bitten by an infected mosquito in the future 
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 I am permanently protected from vivax malaria after I take Primaquine 
 I do not know 
 
27. Taking 1 dose (1 tablet) of Primaquine if patient has falciparum malaria helps the community 
by lowering the risk of malaria spread. 
 
 True    False   I do NOT know 
 
28. Taking 1 dose (1 tablet) of Primaquine by a patient with falciparum malaria is generally safe, 
for patients with normal and G6PD deficient status. 
 
 True    False   I do NOT know 
 
29. Taking 2 weeks course of Primaquine by a patient with vivax malaria is safe, without G6PD 
testing. 
 
 True    False   I do NOT know 
 
30. If urine suddenly becomes dark, cola-colored (shown below), the patient should: 
 
31. Pregnant women and women who are breastfeeding can take Primaquine safely. 
 
 True    False   I do NOT know 
 
32. What is the benefit of Primaquine treatment for a patient with P. falciparum?  
 No benefit, treatment is NOT recommended 
 Benefit is small  
 The community can benefit by lowering the risk of malaria transmission to 
others  
 I do NOT know 
 
33. How beneficial is Primaquine treatment for a patient with P. vivax?  
 No benefit, treatment is NOT recommended 
 Benefit is small  
 Majority of patients can benefit from treatment (it is required for cure) 
 I do NOT know  
34. How long do you have to wait before reading G6PD RDT results (CareStartTM)? 
 2 min    5 min   10 min 
 15 min    I don’t know 
 Seek medical care immediately 
 Monitor this situation over the next 3-5 
days 
 Continue taking Primaquine to make sure 
can be cured from malaria 
 I do NOT know 
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35. What can affect the test performance of G6PD screening test such as CareStartTM? (select all 
that apply): 
 Temperature >32 degrees 
 Novice user not familiar with the color interpretation 
 Reading of the test at 15 mins rather than 10 mins 
 I do NOT know 
 
36. When interpreting the G6PD RDTs, the patient is G6PD deficient when: (SELECT ALL 
THAT APPLY)? 
 The color in the reading window is WHITE 
 The color in the reading window is PURPLE 
 The color in the reading window is VERY FAINT PURPLE 
 I do NOT know 
 
37. A male patient has G6PD result shown below, what do you recommend next? 
    
 
 
 
38. A male patient has G6PD result shown below, would you recommend 
Primaquine? 
 
 
 
 
 
 
39. A mother comes to the clinic and informs you that she is feeling tired and her lips look pale 
after taking her husband’s anti-malaria treatment. On inquiry, you discover he was prescribed 
Primaquine a week ago and felt better quickly, so he shared his remaining medications with 
his wife who he thought also had malaria. What is the most important step you should take at 
this time? 
 Prescribe additional tablets of Primaquine so the patient has enough to finish 2 weeks’ 
course 
 Discharge home with instruction to return if she develops a fever  
 Immediately refer to the nearest hospital for urgent evaluation 
 I do NOT know 
ACCEPTABILITY OF G6PD TESTING AND PRIMAQUINE 
TREATMENT 
[Please Check () or Mark (X) to select your answer] 
 Treatment with Primaquine 
 Counsel the patient that he/she is G6PD 
deficient 
 Repeat the test 
  I don’t know 
 
 Yes 
 No 
 I 
don’t 
know 
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G6PD TESTING 
 
40. How reliable is G6PD screening test for male patients (Rapid Diagnostic Test such as 
CareStartTM): 
    Not reliable                Very Reliable  
1 2 3 4 5 6 7 
       
   
   I do NOT know 
 
41. How reliable is G6PD screening test for female patients (Rapid Diagnostic Test such as 
CareStartTM): 
 
   Not reliable               Very Reliable  
 
1 2 3 4 5 6 7 
       
 
   I do NOT know 
 
42. G6PD screening tests should be made available at the following locations (select all that 
apply): 
 
 In the village, testing by Village Malaria Worker 
 Health clinic 
 Hospital  
 
43. Are you willing to test patients for G6PD deficiency every time they have malaria? 
 
   Yes    No    I do NOT know 
 
44. How comfortable are you providing Primaquine treatment based on the G6PD Rapid 
Diagnostic Tests only:  
 
         Not comfortable          Very comfortable 
1 2 3 4 5 6 7 
       
 
45. Are you willing to use G6PD screening test if it can misclassify few patients who are 
deficient as being normal (due to test limitations, some tests many give incorrect result)? 
 
  Not acceptable                     Acceptable 
 
1 2 3 4 5 6 7 
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   I do NOT know 
 
46. In your view, what is the likelihood of G6PD rapid test showing wrong result? 
 
         Very low                      Very high 
1 2 3 4 5 6 7 
       
 
   I do NOT know 
 
47. What are your thoughts about G6PD screening with RDTs? 
☐ I am supportive, reason:  
☐ I am not supportive, reason:  
  ☐ I am not sure  
PRIMAQUINE RISK 
 
48. How willing are you to give Primaquine to a patient with P. vivax malaria and normal 
G6PD test? 
        Not willing              Willing  
1 2 3 4 5 6 7 
       
 
   I do NOT know 
49. How willing are you to give Primaquine single dose treatment for P. falciparum for a patient 
NOT screened for G6PD deficiency? 
 
    Not willing              Willing 
1 2 3 4 5 6 7 
       
 
   I do NOT know 
 
Comments: _____________________________________________________________ 
50. How willing are you to give 2 week course treatment of Primaquine to MALE 
patients with vivax malaria and normal G6PD status (based on CareStartTM RDT)? 
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   Not willing             Willing 
1 2 3 4 5 6 7 
       
 
   I do NOT know 
 
51. How willing are you to prescribe 2 week course treatment with Primaquine to FEMALE 
patients with vivax malaria and normal G6PD status (based on CareStartTM RDT)? 
 
   Not likely        Very Likely 
1 2 3 4 5 6 7 
       
 
   I do NOT know 
 
52. In your view, what is the risk of single dose treatment with Primaquine, when test shows 
you are G6PD deficient (based on CareStartTM RDT)? 
 
   No risk                                                                                  Very high risk 
 
1 2 3 4 5 6 7 
       
 
   I do NOT know 
53. In your view, how high is the risk of single dose treatment with Primaquine, when test 
shows you are G6PD normal (based on CareStartTM RDT)? 
 
         No risk                                                                                  Very high risk 
1 2 3 4 5 6 7 
       
 
   I do NOT know 
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54. In your view, how high is the risk of 2 week course treatment with Primaquine when test 
shows you are G6PD deficient (based on CareStartTM RDT)? 
         No risk                                                                                  Very high risk 
1 2 3 4 5 6 7 
       
 
   I do NOT know 
55. In your view, how high is the risk of 2 week course treatment with Primaquine, when test 
shows you are G6PD normal (based on CareStartTM RDT)? 
         No risk                                                                                  Very high risk 
1 2 3 4 5 6 7 
       
 
   I do NOT know 
56. Please select if the treatment with Primaquine results in greater risk or benefit, for the 
following scenarios: 
Malaria Primaquine  G6PD 
status 
Greater 
benefit 
Greater 
risk 
I 
don't 
know 
P.falciparum single dose 
(1 tablet) 
deficient    
P.falciparum single dose 
(1 tablet) 
normal    
P.vivax 2 week 
course  
deficient     
P.vivax 2 weeks 
course 
normal    
 
57. How confident are you in performing RDTs for G6PD screening correctly?  
   Not confident                       Very confident 
1 2 3 4 5 6 7 
       
     
   I do NOT know 
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58. How confident are you in your interpretation of the results of the G6PD screening test 
based on the color change (CareStartTM RDT kit)  
 
   Not confident              Very confident 
1 2 3 4 5 6 7 
       
 
   I do NOT know 
 
59. Do you have any additional comments? 
 Yes: _____________________________________________ 
 No 
60. Which questions did you find confusing or in your view, should be removed (list the 
corresponding numbers)? 
Completed by: _____________________ 
(Trainee) 
 
 
Reviewed form completeness by: _____________________ 
(Researcher or Designee) 
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Appendix K: CareStart™ Equipment 
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Point out the expiry date on the test packet, but do not read the date.  
Pass the test packet around and ask each participant to look at it. 
Allow participants to go through the process of hands-on training to ensure they can read 
expiration date and follow the steps for processing the sample. 
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APPENDIX 
Steps for testing G6PD Status in field setting using CareStart™ 
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APPENDIX L: G6PD normal Vs deficient among Males/Females 
 
APPENDIX M: Flow Chart  
 
(Global Malaria 
Program, 2016) 
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Appendix N1: G6PD Trainee Checklist 
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Appendix O: PATIENT COUNSELING SCRIPT (ENGLISH) 
INFORMATION ABOUT PRIMAQUINE & G6PD SCREENING 
G6PD deficiency 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is recommended that G6PD normal patients who have vivax malaria receive treatment with 
Primaquine every day for 14 days. Patients who have falciparum malaria should receive a single 
dose of Primaquine. However, all patients require testing to confirm they have normal G6PD 
levels, before receiving treatment with Primaquine.   
Some people have a low amount of a 
substance called glucose-6-phosphate 
dehydrogenase (G6PD) in the cells that 
carry oxygen in the blood around the body. 
These people have what is called G6PD 
deficiency. Most people with low G6PD 
levels never know they are different, and 
they do not show symptoms unless they take 
certain medications, such as Primaquine.  
If the patient has a low amount of G6PD, their red blood cells can get broken or burst more easily. 
Current malaria treatment 
recommendations in Cambodia 
 
Current treatment guidelines in Cambodia 
recommend that all malaria patients receive 
antimalarial drugs called artemisinin-based 
combination therapy (ACT) for 3 days. 
Patients with malaria should also receive 
treatment with Primaquine, as long as they 
have normal levels of G6PD in their red blood 
cells.   
Primaquin
G6PD normal 
G6PD deficient 
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Why is Primaquine recommended  
for malaria treatment? 
 
If a patient has vivax malaria and does NOT get treatment with Primaquine, they can have parasites 
that stay hidden in the liver and enter blood several months later, which will make the patient sick 
again with malaria symptoms.  
 
To get rid of these parasites from the liver, the patient needs to take Primaquine.  
For patients who have falciparum malaria, it is recommended that 
they take one dose of Primaquine in order to reduce the risk of 
transmission of malaria to other people. This means fewer people 
will be able to transmit malaria in the community, so the risk of 
getting malaria when they get bitten by a mosquito may be lower.     
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Primaquine G6PD test kit 
G6PD testing was not available in 
Cambodia, so Primaquine was not used, 
but the National Malaria Program (CNM) 
would like to make testing and Primaquine 
more widely available for malaria patients, 
in support of Cambodia malaria 
elimination strategy.  
What are the risks of treatment with Primaquine? 
For patients with NORMAL G6PD levels, taking Primaquine is generally very well tolerated without any 
issues.  
 
But taking Primaquine is NOT recommended for people with G6PD deficiency, as the breakdown of the 
red blood cells can make them ill. The most common symptoms are fatigue, shortness of breath after 
activity, rapid breathing, pallor, and increased heart rate, yellowing of skin and eyes, or dark, tea colored 
urine or back pain.  In most cases, this can be corrected by stopping Primaquine treatment when these 
symptoms develop. Patients with NORMAL G6PD levels are very unlikely to develop these symptoms 
with Primaquine.   
If someone’s G6PD levels are very low, Primaquine treatment could result in a large number of their 
red blood cells being destroyed.  Therefore, in rare cases, some patients treated with Primaquine may 
need a blood transfusion to replace the red blood cells that burst after Primaquine treatment.  This is 
very unlikely for patients with normal G6PD levels  
 
STOP Primaquine 
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What are the benefits of PQ treatment? 
It is suspected that many patients have vivax recurrence due to lack of treatment with Primaquine, 
which allows the hidden parasites in the liver to enter the patient’s blood many times.  Taking 
Primaquine when a patient is diagnosed with vivax will kill and eliminate hidden parasites in their 
liver and make them less likely to have recurrence of the infection. However, it is still possible for 
a patient to get vivax in the future if they get bitten again by an infected mosquito. 
Taking Primaquine when a patient has falciparum malaria will make them less likely to transmit 
the infection to other people, which may reduce their own risk of getting infected again.   
Limitations of the current tests for G6PD screening: 
There are different tests for G6PD deficiency but most of them are not suitable for use outside of 
a highly specialized laboratory setting.   The test for G6PD deficiency which is being used today 
comes with limitations as outlined below: 
The risks of Primaquine treatment are based on patient’s G6PD level, how many doses of Primaquine 
they take and other factors.  Risk can be minimized if a patient has normal or near normal levels of 
G6PD.   
The risk from Primaquine treatment is also considered very low for falciparum patients since they 
only have to take a single dose. Single dose treatment is unlikely to result in significant destruction 
of red blood cells, even for patients with low levels of G6PD.   It is therefore acceptable to take 
SINGLE dose of Primaquine for falciparum malaria without G6PD testing.  
Lack of treatment with Primaquine in patients with vivax malaria also poses risks to patients as this can 
result in frequent recurrences of vivax malaria.  Having malaria recurrence frequently can affect your 
ability to work or take care of your family.   
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1. The rapid diagnostic test for G6PD deficiency 
requires interpretation of a color change, which can 
sometimes be difficult, or color change can be 
misinterpreted even by highly trained medical staff.  
2. The reliability of the test may be compromised if the 
testing is done in the room with more than 32 degrees 
Celsius. 
3. The rapid diagnostic test can only tell if a patient has 
NORMAL or LOW levels of G6PD.  These tests 
cannot tell how much of the G6PD enzyme the 
patient has.   
Therefore, it is recommended that even with 
NORMAL G6PD test result, all patients are 
monitored for possible side effects from taking Primaquine.   
Understanding your test results: 
 
 
 
 
 
 
 
 
 
 
If your test result is normal it means you 
should have sufficient levels of the G6PD 
enzyme to receive Primaquine safely  
If the test shows you are G6PD deficient, this means that taking Primaquine for 14 days could 
damage some of your red blood cells and might make you feel sick. This can manifest as you 
being pale, having shortness of breath with activity, having a yellow pigmentation of the skin or 
eyes, or tea-colored urine.  So treatment with Primaquine is not recommended for vivax malaria 
when you are G6PD deficient.  However, single dose of Primaquine for falciparum malaria is 
normally tolerated even in patients with G6PD deficiency; therefore, it is recommended to reduce 
risk of transmission to others.     
 
Given the limitations of the tests, if you are given 
Primaquine and develop the above mentioned 
symptoms or any new symptoms within 2 weeks of 
taking Primaquine, you should visit your doctor 
immediately. If your local health center is closed, 
then you should go to the nearest hospital. 
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APPENDIX P: Descriptive Statistical Table for Trainees 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Total sample  (%) 
Trainee 
   VMW 
   Nurse 
   Other 
94 
68 
21 
5 
100 
72.3 
22.3 
5.4 
Age Group Trainees   
<30yrs 29 30.9 
31-50yrs 51 54.3 
>51yrs 14 14.9 
Gender  
   Male 
   Female 
 
 
40 
54 
 
 
42.6 
57.4 
Educational Level   
Primary grade  
(1-6) 
39 41.5 
Secondary  30 31.9 
High school 14 14.9 
College graduate 8 8.5 
Medical Doctor 1 1.1 
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Appendix Q: Results from Study 
Trainee score Pre and Post Training based on Years of Experience 
I. 
 
II 
 
 
 
 
38 37.5 41 37.33
91.33 89.5
78.67
91.2
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III 
 
 
 
IV 
The percentage mean score knowledge pre-training and post-training (p<0.001) 
 PRE-TRAINING POST-TRAINING 
Willingness to test for 
G6PD when a patient 
is diagnosed with 
malaria 
56.3% (53/94) 80.8%(76/94) 
Level of comfort in 
giving PQ based on 
G6PD RDT results 
39.3% (37/94) 72.3% (68/94) 
Level of comfort in 
giving PQ to a patient 
with P.v and normal 
G6PD test 
36.1%(34/94) 80.0% (76/94) 
Willingness to give a 
patient  PQ single 
dose for Pf without 
G6PD screening 
20.2%( 19/94) 84% (79/94) 
 VMWs Nurses Other 
Pre-Training 34% 56.4% 34% 
Post-Training 88.71% 90% 96% 
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V 
Knowledge Score Assessment Among 1st group only 
 
Acceptability to Test for G6PD Pre and Post Training 
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Willingness to Prescribe PQ for P.v 
 
 
VII (Willingness and Acceptance) 
Q: Are you willing to test patients for G6PD deficiency every time they have 
malaria? 
 
   Yes    No    I do NOT know 
 
 
 
33%
11%
56%
Pre
Unsure
No
Yes
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Q: How willing are you to give Primaquine to a patient with P. vivax malaria and 
normal G6PD test? 
 
Not willing                      Willing  
1 2 3 4 5 6 7 
 
   I don’t know 
 
 
 
 
 
 
 Q: How willing are you to give Primaquine single dose treatment for P. 
falciparum for a patient NOT screened for G6PD deficiency? 
    
     Not willing                       Willing 
1 2 3 4 5 6 7 
 
   I don’t know 
 
Pre
Post0 1 2
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0 0 3 1
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Pre Post
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Pre Post
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Appendix Figure 1: Variables           
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(perception of threat, susceptibility, 
seriousness)
Independent Variables        Dependent Variables 
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Appendix Figure 2: G6PD color changes 
 
